Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Breast cancer].

Yutaka Tokuda1, Yuki Saito, Yasuhiro Suzuki

  • 1Department of Breast and Endocrine Surgery, Tokai University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.

Anticancer research·2022
Same author

The association of <i>ACTN3</i> R577X polymorphism with sports specificity in Japanese elite athletes.

Biology of sport·2022
Same author

Effects of Branched-Chain Amino Acids on Skeletal Muscle, Glycemic Control, and Neuropsychological Performance in Elderly Persons with Type 2 Diabetes Mellitus: An Exploratory Randomized Controlled Trial.

Nutrients·2022
Same author

Marked Reduction of Cerebral Vasospasm with Intrathecal Urokinase Infusion Therapy after Endovascular Coil Embolization of the Aneurysmal Subarachnoid Hemorrhage: A Case Series.

Neurologia medico-chirurgica·2022
Same author

Antemortem Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Recurrent Breast Cancer: An Autopsy Case Report.

The Tokai journal of experimental and clinical medicine·2022
Same author

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Cancer science·2022

The humanized anti-HER2 monoclonal antibody, trastuzumab (Herceptin), targets HER2/neu protein for cancer therapy. Clinical trials show its effectiveness in treating breast cancer overexpressing the HER2/neu gene.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Context:

  • The HER2/neu protein is a significant target in cancer therapy due to its overexpression in certain malignancies.
  • The development of targeted therapies is crucial for improving cancer treatment outcomes.

Purpose:

  • To review the details of trastuzumab (Herceptin), a novel biologic agent.
  • To present the clinical trial results for trastuzumab in breast cancer patients.

Summary:

  • Trastuzumab is a recombinant humanized monoclonal antibody designed to target the HER2/neu protein.
  • This antibody has demonstrated efficacy in clinical trials for breast cancer exhibiting HER2/neu gene overexpression.
  • Its availability in Japan marks a significant advancement in antibody therapy for HER2-positive cancers.

Related Experiment Videos

Impact:

  • Trastuzumab offers a targeted therapeutic strategy for HER2/neu-overexpressing cancers, particularly breast cancer.
  • The review provides valuable insights into the clinical application and efficacy of this biologic agent.
  • This contributes to the growing field of personalized medicine in oncology.